Amendments to the Claims/Listing of Claims

Please amend claims 73, 103, 107 and 108, cancel non-elected claims 29-35, 46-67, 70-72, 76-100 and 109-121 without prejudice, and add new claims 122-133 as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

1-72. (Canceled).

73. (Currently amended) An article of manufacture comprising a dry powder or liquid formulation of drug and at least one protein, wherein said formulation comprises drug nanoparticles that have been filtered through a sterilizing filter coated with said protein, and wherein said drug nanoparticles are in amorphous form.

74. (Previously presented) An article of manufacture according to claim 73 wherein said drug is a taxane.

75. (Previously presented) An article of manufacture according to claim 74, wherein said liquid formulation of taxane is free of surfactants.

76-100. (Canceled)

101. (Previously presented) An article of manufacture according to claim 73 wherein said protein is albumin.

102. (Previously presented) An article of manufacture according to claim 73 wherein said nanoparticle is solid or liquid.

103. (Currently amended) An article of manufacture according to claim 73 wherein said drug is selected from the group consisting of an anti-neoplastic, an immunosuppressive, and an anesthetic.
104. (Previously presented) An article of manufacture according to claim 103 wherein said anti-neoplastic is a taxane.

105. (Previously presented) An article of manufacture according to claim 103 wherein said anesthetic is propofol.

106. (Canceled).

107. (Currently amended) A formulation **an article of manufacture** according to claim 73 wherein said drug is non-crystalline.

108. (Currently amended) A formulation **an article of manufacture** according to claim 73 wherein said nanoparticles are suitable for administration to a subject by oral, topical, ocular, intramuscular, intravenous, intraperitoneal, intraarterial, intraurethral, intrathecal, or inhalation administration.

109-121. (Cancelled)

122. (New) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by oral administration.

123. (New) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by topical administration.

124. (New) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by ocular administration.
125.  (New) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by intramuscular administration.

126.  (New) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by intravenous administration.

127.  (New) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by intraperitoneal administration.

128.  (New) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by intraarterial administration.

129.  (New) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by intraurethral administration.

130.  (New) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by intrathecal administration.

131.  (New) An article of manufacture according to claim 73 wherein said nanoparticles are suitable for administration to a subject by inhalation administration.

132.  (New) An article of manufacture according to claim 73 wherein the average diameter of said nanoparticles is in the range of about 0.01 – 1 microns.

133.  (New) An article of manufacture according to claim 103 wherein said immunosuppressive is cyclosporin.